Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

PHASE3CompletedINTERVENTIONAL
Enrollment

396

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

September 10, 2018

Study Completion Date

September 25, 2018

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

Liraglutide 3.0 mg

Injected subcutaneously (s.c., under the skin) once daily

DRUG

Placebo

Injected subcutaneously (s.c., under the skin) once daily

Trial Locations (54)

12206

Novo Nordisk Investigational Site, Albany

14612

Novo Nordisk Investigational Site, Falkensee

22607

Novo Nordisk Investigational Site, Hamburg

28401

Novo Nordisk Investigational Site, Wilmington

30076

Novo Nordisk Investigational Site, Roswell

32205

Novo Nordisk Investigational Site, Jacksonville

33324

Novo Nordisk Investigational Site, Plantation

34096

Novo Nordisk Investigational Site, Istanbul

34303

Novo Nordisk Investigational Site, Istanbul

34371

Novo Nordisk Investigational Site, Istanbul

34890

Novo Nordisk Investigational Site, Istanbul

35152

Novo Nordisk Investigational Site, Haifa

35294

Novo Nordisk Investigational Site, Birmingham

35340

Novo Nordisk Investigational Site, Izmir

40138

Novo Nordisk Investigational Site, Bologna

40213

Novo Nordisk Investigational Site, Louisville

44281

Novo Nordisk Investigational Site, Kfar Saba

44600

Novo Nordisk Investigational Site, Guadalajara

45219

Novo Nordisk Investigational Site, Essen

48145

Novo Nordisk Investigational Site, Münster

49372

Novo Nordisk Investigational Site, Petah Tikva

52621

Novo Nordisk Investigational Site, Tel Litwinsky

55416

Novo Nordisk Investigational Site, Minneapolis

59701

Novo Nordisk Investigational Site, Butte

60607

Novo Nordisk Investigational Site, Chicago

64239

Novo Nordisk Investigational Site, Tel Aviv

64620

Novo Nordisk Investigational Site, Monterrey

66386

Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach

66780

Novo Nordisk Investigational Site, Rehlingen-Siersburg

75230

Novo Nordisk Investigational Site, Dallas

75231

Novo Nordisk Investigational Site, Dallas

78731

Novo Nordisk Investigational Site, Austin

78749

Novo Nordisk Investigational Site, Austin

80131

Novo Nordisk Investigational Site, Napoli

90127

Novo Nordisk Investigational Site, Palermo

91120

Novo Nordisk Investigational Site, Jerusalem

93720

Novo Nordisk Investigational Site, Fresno

94520

Novo Nordisk Investigational Site, Concord

96814

Novo Nordisk Investigational Site, Honolulu

02747

Novo Nordisk Investigational Site, North Dartmouth

22601-3834

Novo Nordisk Investigational Site, Winchester

T2V 4J2

Novo Nordisk Investigational Site, Calgary

T6H 2L4

Novo Nordisk Investigational Site, Edmonton

B3H 2Y9

Novo Nordisk Investigational Site, Halifax

L8L 5G8

Novo Nordisk Investigational Site, Hamilton

N6A 5B7

Novo Nordisk Investigational Site, London

M6G 1M2

Novo Nordisk Investigational Site, Toronto

N2J 1C4

Novo Nordisk Investigational Site, Waterloo

G1V 4G5

Novo Nordisk Investigational Site, Québec

01307

Novo Nordisk Investigational Site, Dresden

04103

Novo Nordisk Investigational Site, Leipzig

00168

Novo Nordisk Investigational Site, Rome

06500

Novo Nordisk Investigational Site, Ankara

07058

Novo Nordisk Investigational Site, Antalya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY